Gynica

Executive Summary

Gynica is an Israeli biotech company pioneering non-hormonal, intra-vaginal therapies for endometriosis. Its proprietary IntraVag microencapsulation platform delivers cannabinoid APIs directly to the vaginal cavity, aiming to reduce pain and symptoms with minimal systemic exposure. Founded in 2020, the company targets a large unmet need in women's health, as current endometriosis treatments often involve hormones or surgery with significant side effects. Gynica's approach leverages the endocannabinoid system's role in pain and inflammation, potentially offering a safer, more targeted alternative. The company is currently in the Phase 1 stage and has raised an undisclosed amount, positioning it as an early-stage player in a growing market estimated at over $2 billion annually. Its differentiated delivery technology and focus on a debilitating condition provide a strong value proposition, though clinical validation remains pending.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial70% success
• Q2 2027Partnership or Licensing Deal for IntraVag Platform30% success
• Q1 2027Series A Financing Round60% success